Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-07832837 · 1 trial · 2 indications
An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or other important medical events. An AE was considered as treatment emergent if the event started during the effective duration of treatment. All events that started on or after the first dosing day up to the last dose plus the lag time were considered as TEAEs.
Number of participants with any laboratory test abnormalities meeting pre-defined criteria was reported in this outcome measure.
Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, corrected QT (QTc) intervals and QRS complex. Clinically significant findings were determined by the investigator.
Vital signs included blood pressure, pulse rate, respiratory rate, oxygen saturation and oral temperature. Clinically significant findings were determined by the investigator.
Cardiac telemetry was collected in Part 1 SAD cohorts only. Number of participants with any cardiac telemetry abnormalities were reported in this outcome measure.
An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or other important medical events. An AE was considered as treatment emergent if the event started during the effective duration of treatment. All events that started on or after the first dosing day up to the last dose plus the lag time were considered as TEAEs.
Number of participants with any laboratory test abnormalities meeting pre-defined criteria was reported in this outcome measure.
Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, corrected QT (QTc) intervals and QRS complex. Clinically significant findings were determined by the investigator.
An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or other important medical events. An AE was considered as treatment emergent if the event started during the effective duration of treatment. All events that started on or after the first dosing day up to the last dose plus the lag time were considered as TEAEs.
Number of participants with any laboratory test abnormalities meeting pre-defined criteria was reported in this outcome measure.
Vital signs included blood pressure, pulse rate, respiratory rate, oxygen saturation and oral temperature. Clinically significant findings were determined by the investigator.
| Arm | Type | Description |
|---|---|---|
| PF-07832837 | EXPERIMENTAL | single or multiple doses of PF-07832837 at ascending dose levels |
| placebo | PLACEBO_COMPARATOR | single or multiple doses of placebo |
| Name | Type | Description |
|---|---|---|
| PF-07832837 | DRUG | escalated doses of PF-07832837 |
| Placebo | OTHER | placebo |
Inclusion Criteria: * Part 1 only: Adult participants between 18 to 55 years of age, inclusive, at the time of signing the ICD * Part 2 only: Adult participants, who at the time of screening, are between the ages of 18 and 70 years, inclusive. * Part 1 only: Participants who are overtly healthy as ...
PF-07832837 is an investigational small molecule being studied for use in healthy participants and in patients with atopic dermatitis. It is currently in Phase 1 clinical development, and its safety and tolerability are being evaluated in a first-in-human study.
PF-07832837 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development.
PF-07832837 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A first-in-human study is currently recruiting participants to evaluate its tolerability.
PF-07832837 is being studied in a Phase 1 first-in-human trial with the identifier NCT06564389. This randomized, double-blind, placebo-controlled study is recruiting 119 participants in the United States and includes healthy adults and patients with atopic dermatitis.
Yes, PF-07832837 is being studied in atopic dermatitis. The ongoing Phase 1 trial, NCT06564389, includes patients with atopic dermatitis as well as healthy participants. The study is evaluating the tolerability of the drug in these populations.